TY  - JOUR 
AU  - Torrent, Anna
AU  - Morgades, Mireia
AU  - García-Calduch, Olga
AU  - Queipo de Llano, María Paz
AU  - Montesinos, Pau
AU  - Navarro, Irene
AU  - Hernández Rivas, Jesús María
AU  - Bárez García, Abelardo
AU  - González-Campos, José
AU  - Oiartzabal, Itziar
AU  - Valero, Marta
AU  - Cervera, Marta
AU  - Zudaire, Teresa
AU  - Albors Ferreiro, Manuel
AU  - López Godino, Oriana Jimena
AU  - Gil Cortés, Cristina
AU  - Villalón, Lucía
AU  - Saldaña, Raquel
AU  - Ribera, Josep-María
PY  - 2023
UR  - http://hdl.handle.net/10366/171851
AB  - [EN]The prognosis of relapsed B cell precursor acute lymphoblastic leukemia (B-ALL) is poor and few patients can be successfully rescued with conventional therapies. Inotuzumab ozogamicin (IO), an antibody against the CD22 antigen linked to...
LA  - eng
PB  - Wiley
KW  - Precursor Cell Lymphoblastic Leukemia-Lymphoma
KW  - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
KW  - Humans
KW  - Adult
KW  - Young Adult
KW  - Middle Aged
KW  - Aged
KW  - Inotuzumab Ozogamicin
KW  - Spain
KW  - Retrospective Studies
KW  - Antibodies, Monoclonal, Humanized
KW  - Aged
KW  - Young Adult
KW  - Precursor Cell Lymphoblastic Leukemia-Lymphoma
KW  - Adult
KW  - Humans
KW  - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
KW  - Antibodies, Monoclonal, Humanized
KW  - Middle Aged
KW  - Retrospective Studies
TI  - Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain
DO  - 10.1111/ejh.14031
T2  - European journal of haematology
VL  - 111
M2  - 485
ER  -